130 related articles for article (PubMed ID: 37815923)
1. Clinical outcomes of
Hansen KH; Johansen JS; Urbanska EM; Meldgaard P; Hjorth-Hansen P; Kristiansen C; Stelmach M; Santoni-Rugiu E; Ulhøi MP; Dydensborg AB; Dünweber C; Andersen JL
Acta Oncol; 2023 Dec; 62(12):1775-1783. PubMed ID: 37815923
[TBL] [Abstract][Full Text] [Related]
2. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
3. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
[TBL] [Abstract][Full Text] [Related]
4. Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration - a Swedish nationwide retrospective study.
Lauppe R; Nilsson FOL; Fues Wahl H; Lilja M; Vikström A; T Asanin S
Acta Oncol; 2022 Nov; 61(11):1354-1361. PubMed ID: 36368902
[TBL] [Abstract][Full Text] [Related]
5. Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.
Miloš P; Jana S; Vítězslav K; Monika Š; Leona K; Jaromír R; Renata C; Markéta Č; Andrea B; Juraj K; Michal H; Milada Z; Marek K; Helena Č; Martin S
Klin Onkol; 2018; 31(3):207-212. PubMed ID: 30441974
[TBL] [Abstract][Full Text] [Related]
6. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Wu Y; Nordstrom B; Socinski MA
Oncologist; 2020 Oct; 25(10):867-877. PubMed ID: 32490560
[TBL] [Abstract][Full Text] [Related]
7. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
8. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
[TBL] [Abstract][Full Text] [Related]
9. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
[TBL] [Abstract][Full Text] [Related]
10. ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.
Wang M; Slatter S; Sussell J; Lin CW; Ogale S; Datta D; Butte AJ; Bazhenova L; Rudrapatna VA
Target Oncol; 2023 Jul; 18(4):571-583. PubMed ID: 37341856
[TBL] [Abstract][Full Text] [Related]
11. Overall Survival of Patients With
Tsimafeyeu I; Moiseenko F; Orlov S; Filippova E; Belonogov A; Nebesnykh A; Khalimov A; Karabina E; Shikina V; Abdelgafur A; Statsenko G; Titova I; Isaichikov D; Makarnyaeva G; Mordovskiy A; Barkovskaya O; Smirnov A; Gikalo M; Savelov N; Kosov D; Imyanitov E; Demidova I; Tjulandin S
J Glob Oncol; 2019 May; 5():1-7. PubMed ID: 31095455
[TBL] [Abstract][Full Text] [Related]
12. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
[TBL] [Abstract][Full Text] [Related]
13. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract][Full Text] [Related]
14. Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients.
Davies J; Martinec M; Coudert M; Delmar P; Crane G
Curr Med Res Opin; 2019 Mar; 35(3):535-542. PubMed ID: 30296185
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.
Chiari R; Metro G; Iacono D; Bellezza G; Rebonato A; Dubini A; Sperduti I; Bennati C; Paglialunga L; Burgio MA; Baglivo S; Giusti R; Minotti V; Delmonte A; Crinò L
Lung Cancer; 2015 Nov; 90(2):255-60. PubMed ID: 26395848
[TBL] [Abstract][Full Text] [Related]
16. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
[No Abstract] [Full Text] [Related]
17. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
[TBL] [Abstract][Full Text] [Related]
18. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
[TBL] [Abstract][Full Text] [Related]
19. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study.
Gobbini E; Chiari R; Pizzutillo P; Bordi P; Ghilardi L; Pilotto S; Osman G; Cappuzzo F; Cecere F; Riccardi F; Scotti V; Martelli O; Borra G; Maiello E; Rossi A; Graziano P; Gregorc V; Casartelli C; Sergi C; Del Conte A; Delmonte A; Bareggi C; Cortinovis D; Rizzo P; Tabbò F; Rossi G; Bria E; Galetta D; Tiseo M; Di Maio M; Novello S
Clin Transl Oncol; 2020 Mar; 22(3):294-301. PubMed ID: 31630357
[TBL] [Abstract][Full Text] [Related]
20. Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.
Schmid S; Cheng S; Chotai S; Garcia M; Zhan L; Hueniken K; Balaratnam K; Khan K; Patel D; Grant B; Raptis R; Brown MC; Xu W; Moriarty P; Shepherd FA; Sacher AG; Leighl NB; Bradbury PA; Liu G
Clin Lung Cancer; 2023 Jan; 24(1):40-50. PubMed ID: 36270866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
